Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System

Coronary Artery Disease Clinical Trial

— DIRECT II  

Official title:

Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01788150
• Other study ID #: IP-12-002
• Status: Completed
• Phase: N/A
• Start date: January 2013
• Est. completion date: May 31, 2019

Study information

• Verified date: April 2021
• Source: Svelte Medical Systems, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, randomized, active-control, multi-center clinical trial comparing the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to that of the commercially available Resolute IntegrityTM Drug-Eluting Stent.

The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, never previously treated coronary artery lesions

Recruitment information / eligibility

• Status: Completed
• Enrollment: 159
• Est. completion date: May 31, 2019
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

General Inclusion Criteria

1. Patient is =18 years old;

2. Patient is eligible for percutaneous coronary intervention (PCI);

3. Patient is an acceptable candidate for emergent coronary artery bypass graft (CABG) surgery;

4. Patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study;

5. Female subjects of childbearing potential must have a negative pregnancy test within 7-days before the trial procedure;

6. Patient or subject's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Hospital Research Ethics Committee (HREC) of the respective investigational site; and

7. Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.

Angiographic Inclusion Criteria

1. Patient has either a single target lesion, or two lesions (target and non-target) located in separate coronary arteries;

2. If a non-target lesion is treated, it must be treated first and only with commercially available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the following conditions must be met:

1. Residual diameter stenosis < 30%;

2. Absence of any angiographic complications;

3. Absence of ischemic symptoms; and

4. Absence of significant new arrhythmia or ECG monitoring changes suggestive of ischemia.

3. Reference vessel = 2.5 mm and = 3.5 mm in diameter by visual estimate;

4. Target lesion < 20 mm in length by visual estimate (the intention is to cover the entire lesion with one stent of adequate length); and

5. Target lesion stenosis = 50% and < 100% by visual estimate.

Exclusion Criteria:

General Exclusion Criteria

1. Patient is currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials;

2. The patient requires a staged procedure of the target vessel within 6-months or a staged procedure of a non-target vessel within 30-days post-procedure;

3. The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.);

4. Any DES deployment anywhere in the target vessel within the past 9-months;

5. Any BMS deployment anywhere in the target vessel within the past 6-months;

6. Any previous stent placement within 10 mm (proximal or distal) of the target lesion;

7. Myocardial infarction within 72-hours of the index procedure, with the exception of:

1. Patients who have had a STEMI and PCI to the culprit lesion may be included if they have a suitable lesion in another vessel, and have been clinically and hemodynamically stable for 72-hours;

2. Patients who have had a non-STEMI may be included if their troponin levels are within the laboratory normal range within 24-hours pre-procedure.

8. Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial;

9. Concurrent medical condition with a life expectancy of less than 12-months;

10. Documented left ventricular ejection fraction (LVEF) = 30%;

11. Unstable angina pectoris from an extra-cardiac cause (Braunwald Class A I-III);

12. Known allergies to the following: Acetylsalicylic acid (ASA), Clopidogrel bisulfate, Ticlopidine, Prasugrel, Rapamycin, Zotarolimus, PEAIII AcBz, Heparin/ Bivalirudin, or contrast agent (that cannot be adequately premedicated);

13. Platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 or a WBC < 3.000 cells/mm3 or hemoglobin < 100g/l;

14. Acute or chronic renal dysfunction (serum creatinine > 170µmol/L);

15. History of a stroke or transient ischemic attack (TIA) within the prior 6-months;

16. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6-months;

17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions; and

18. Patients requiring ongoing anticoagulation with warfarin or dabigatran.

Angiographic Exclusion Criteria

1. Total occlusion (TIMI 0 or 1);

2. Target vessel has angiographic evidence of thrombus

3. Target vessel is excessively tortuous or has heavy calcification;

4. Significant (> 50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off;

5. Target lesion is located in or supplied by an arterial or venous bypass graft;

6. Ostial target lesion (within 5.0 mm of vessel origin) or any location within the left main coronary artery;

7. Target lesion involves a side branch > 2.0 mm in diameter; and

8. Unprotected Left Main coronary disease (stenosis > 50%).

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Device:
• Coronary Stenting

Locations

Country	Name	City	State
Belgium	OLV Ziekenhuis Aalst	Aalst
Belgium	Middelheim Ziekenhuis	Antwerpen
Belgium	ZOL Genk	Genk
Belgium	CHU Liège	Liege
Czechia	Všeobecná fakultní nemocnice Praha	Prague
France	Clinique Saint-Hilaire	Rouen
France	CHU de Toulouse	Toulouse
France	Clinique Pasteur	Toulouse
Germany	Medizinisches Verzorgungszentrum Prof. Mathey, Prof. Schofer	Hamburg
Germany	University Medical Center Hamburg-Eppendorf	Hamburg
Netherlands	OLVG Amsterdam	Amsterdam
Netherlands	Catharina Hospital Eindhoven	Eindhoven
Netherlands	Erasmus MC	Rotterdam
Netherlands	Maasstad Ziekenhuis	Rotterdam
Netherlands	University Medical Center Utrecht, Department of Cardiology	Utrecht
Sweden	Skane University Hospital	Malmo
Sweden	Södersjukhuset	Stockholm
Switzerland	Inselspital	Bern

Sponsors (1)

Lead Sponsor	Collaborator
Svelte Medical Systems, Inc.

Countries where clinical trial is conducted

Belgium,  Czechia,  France,  Germany,  Netherlands,  Sweden,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Angiographic In-Stent Late Lumen Loss (LL)	Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.	6-months post-procedure
Secondary	Number of Participants Clinically-driven Target Lesion Revascularization (TLR)	Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.	1 year post-procedure
Secondary	Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization	Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization	1 year post-procedure
Secondary	Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels	Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels	1 year post-procedure
Secondary	Number of Participants Stent Thrombosis	The sudden occlusion of a stented coronary artery due to thrombus formation.	1 year post-procedure
Secondary	Number of Participants Acute Success Rates	Direct Stenting Success, Lesion Success, Procedure Success and Device Failure	From index procedure to hospital discharge, an average of 24 hours
Secondary	Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate	The rate which restenosis occurs	6-months post-procedure
Secondary	In-stent and In-segment Minimum Lumen Diameter	Smallest diameter in the stent or segment area	6-months post-procedure
Secondary	In-segment Late Lumen Loss	Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram	6-months post-procedure
Secondary	Neointimal Hyperplasia as Measured by OCT	(% lumen volume)	6-months post procedures
Secondary	Strut Coverage	(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)	6-months post procedure
Secondary	Number of Participants Target Vessel Failure	Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.	1 year post procedure

External Links

•   Related Info